MedChemExpress

PI-103

#HY-10162

54
Citing papers
412
Combined citations
Supplier page Find this product

Research areas

PARP inhibition in cancer therapy31DNA Repair Mechanisms16Cancer-related Molecular Pathways6CRISPR and Genetic Engineering5Cancer Genomics and Diagnostics4Cell death mechanisms and regulation4Ovarian cancer diagnosis and treatment4Sirtuins and Resveratrol in Medicine4

Papers citing this product

1
Drivers of AR indifferent anti-androgen resistance in prostate cancer cells
Scientific Reports·2019·73 cit.·DOI
2
Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer
Cell Death and Disease·2022·63 cit.·DOI
3
STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer
npj Breast Cancer·2022·33 cit.·DOI
4
Macrophage migration inhibitory factor (MIF) suppresses mitophagy through disturbing the protein interaction of PINK1-Parkin in sepsis-associated acute kidney injury
Cell Death and Disease·2024·24 cit.·DOI
5
BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy
Journal of Ovarian Research·2023·22 cit.·DOI
6
Paris saponin VII reverses resistance to PARP inhibitors by regulating ovarian cancer tumor angiogenesis and glycolysis through the RORα/ECM1/VEGFR2 signaling axis
International Journal of Biological Sciences·2024·20 cit.·DOI
7
Mitochondrial rewiring drives metabolic adaptation to NAD(H) shortage in triple negative breast cancer cells
Neoplasia·2023·20 cit.·DOI
8
PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i>
Cancer Research Communications·2023·15 cit.·DOI
9
Nuclear IMPDH2 controls the DNA damage response by modulating PARP1 activity
Nature Communications·2024·14 cit.·DOI
10
MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma
Journal of Experimental & Clinical Cancer Research·2023·12 cit.·DOI

Similar products

ProductVendorPricePapers
BEZ235MedChemExpress—24
OmipalisibMedChemExpress—11
ApitolisibMedChemExpress——
GedatolisibMedChemExpress——
GDC-0084MedChemExpress——